Acarix is a Swedish MedTech company marketing the CADScor®System – the innovative, non-invasive and ultra-sensitive analytical device designed to support a reliable and cost-effective rule-out of significant coronary artery disease (CAD) at the very first stage of the diagnostic pathway.

We are committed to bringing about a change in the early warning and assessment of cardiac and vascular diseases. Our latest news can be found below.

2021 05 20

Meet up with Acarix at the SFAM congress in Åre, 19 May-21 May

Read more about the event - Svensk Allmänmedicinsk Kongress 2021

2021 05 07

Acarix: CEO Per Persson presents at Redeye Theme: Medtech & Diagnostics – May 5th

See interview with Per Persson, CEO Acarix

2021 04 13

BioStock Live features the Swedish medtech company Acarix. CEO, Per Persson, gives an update about the company and its product, the CADScor System.

Acarix has recently received market approval for CADScor in the US, and the CEO expects a news-intensive 2021.

2021 02 01

We welcome Tobias Fritz and Nadine Pelzer to the Acarix Team!

We are very happy to announce and welcome our two new colleagues, Tobias Fritz and Nadine Pelzer to the team!

2021 01 28

Per Persson, CEO, Acarix presents at Aktiesparardagen i Lund, SE. Acarix 2021!

Full presentation to be found here: Acarix 2021 at Aktiesparardagen i Lund

2021 01 11

Per Persson, CEO, Acarix one of the key presenters at LSI 2021 Emerging Medtech Summit, US

Review the full program of the event :

2020 11 30

Acarix receives US market approval for the CADScor® System

The US Food and Drug Administration (FDA) has approved the company’s De Novo application for marketing approval of the CADScor®System in the US.

2020 11 11

Redeye Life Science Day 26 november, 2020

Per Persson,CEO, Acarix, presents at Redeye Life Science Day 26 november at 14.30  See presentation live:

2020 09 09

Coordinating investigator on the FILTER study presented ePOSTER at ESC 2020

The ePOSTER "Cost-effectiveness of adding a non-invasive acoustic rule-out test in the evaluation of patients with suspected stable angina pectoris" presented at ESC 2020.

2020 08 26

Acarix genomför företrädesemission på 56 miljoner kronor.

Acarix genomför företrädesemission på 56 miljoner kronor, garanterad till 90 procent med teckningstid mellan 21 augusti och 4 september.

2020 07 17

Per Persson, CEO of Acarix has been selected as an Innovation Leader at the LSI 2021 Emerging Medtech Summit.

At LSI 2021, Mr. Persson will share the story of Acarix and provide timely updates to an audience of medtech investors, strategics, and industry insiders.

2020 06 22

Interview with Dr Remde, Cardiologist in Heidelberg and since several years back a regular user of the CADScor(R)System.

Dr Remde use the CADScor(R) as a routine test in line with other non-invasive tests for ruling out CAD with high likelihood. 

2020 06 04

Per Persson CEO of Acarix invited to participate in Navigator’s new interview series “Pejling”

Per Persson, gives a general update about the company's FDA application as well as the ongoing reimbursement process in Germany and the company's commercialization strategy in Europe

2020 05 20

Redeye Research Interview with Acarix CEO Per Persson

Per Persson, gives a general update about the company's FDA application as well as the ongoing reimbursement process in Germany and the company's commercialization strategy in Europe

2020 05 05


For the first time, the usage of the CADScor® System in a high prevalence cohort is described by M. Renker et al. This prospective randomized cohort was designed as technical study to confirm predicted sensitivity and specificity in a high prevalence patie...

2020 03 03

We are very happy to announce and to welcome our two new colleagues, Henrik Nilsson and Achim Müller to the Acarix team

Henrik Nilsson our new Sales Director for the Nordic Region and Achim Müller our new Sales Manager, Germany will help us to continuously strengthen our presence and develop our business in the Nordic area as well as in the DACH region.

2020 03 03

Acarix prepares the CADScor®System for the the US market

Per Person,  Acarix CEO presented the CADScor® System at the Emerging Medtech Summit in California, USA, last month. Acarix gained interest from several parties interested to support our journey towards presence in the US market.      Last week we had ...

2020 01 13

New Partnership and Distributors in Austria and Switzerland

As an important part of our continued work in creating a better market access for the CADScor (R) System in our key markets, we are happy to announce the following new partnership and Distributors; Neucomed in Austria and Bodenwinkler in Switzerland. This ...

2019 10 28

Acarix represented at Redeye Investor After Work, Scandic Rubinen, Gothenburg

Per Perssons presentation available under news

2019 10 14

Acarix deltar på Aktiedagen den 15 oktober på operaterrassen, Karl XII:s torg, Stockholm

VD Per Persson, presenterar klockan 16.00. Aktiedagen anordnas av Aktiespararna.

2019 10 07

Acarix at DGK Herztage Berlin 10-12 Okt 2019

Meet the expert Dr Klaus Remde at Stand 19 im Foyer, Saal Maritim

2019 09 19

Investor Forum 17 september 2019

Per Persson CEO, Acarix invited to Redeye investor forum.

2019 08 28

Jörg Domes joins Acarix

I am very happy to announce that Jörg Domes will join Acarix in the role of Sales Director on October 1st, 2019. Jörg will take the overall responsibility for Germany, Austria and Switzerland, the DACH region.